AstraZeneca (LON:AZN) has filed paperwork with the FDA for an emergency use authorization (EUA) for AZD7442, a long-acting antibody (LAAB) cocktail, as a COVID-19 prophylaxis. The paperwork filed for the EUA request includes data from the PROVENT and STORM CHASER Phase 3 trials. A Phase 3 trial of AZD7442 showed statistically significant protection against COVID-19 infection. Compared…
AstraZeneca’s AZD7442 reduced risk of symptomatic COVID-19 in trial
The investigational antibody AZD7442 from AstraZeneca (LON:AZN) fared well in the PROVENT study, reading the risk of developing symptomatic COVID-19 by 77% compared to placebo. More than three-quarters of participants in the trial had comorbidities that could potentially reduce their immune response to vaccination. “We need additional approaches for individuals who are not adequately protected by COVID-19…